Our mission is to fight triple negative breast cancer by:
Help us celebrate 5 amazing years of being the first 5K Run/Walk dedicated to raising awareness of triple negative breast cancer (TNBC).
Sunday, September 21, 2014
Lake Merritt Park, Oakland, CA
Saturday, October 4, 2014
Alondra Park, Lawndale, CA
TNBC Day is the only national event solely devoted to raising both awareness of triple negative breast cancer (TNBC) and funds that provide support for those affected by the disease. TNBC day, created by the Triple Negative Breast Cancer Foundation, is comprised of multiple grassroots fundraising events taking place across the country organized by survivors, friends, families, individual and corporate supporters alike to help eradicate triple negative breast cancers and assist those impacted by the disease.
Here are 3 easy ways to participate with Triple Step Toward the Cure:
#1. Pins For a Purpose
Love the look of a good stiletto but hate that they can be uncomfortable after a short time? Well here's one that you can feel good about wearing all day long! Help us celebrate the beauty, grace, and courage of our TNBC warriors by participating in Pins for A Purpose in commemoration of TNBC Day 2014.
Read More »
#2. VEG OUT with Triple Step for TNBC Day!
Come find out how the 2012 LA Times Readers Choice winner has helped thousands eat their veggies and keeps them coming back for more. Veggie Grill El Segundo is helping commemorating TNBC Day 2014 by donating a portion of lunch proceeds from LA residents who stop by and have lunch on Monday, March 3, 2014, between 11 and 4pm.
#3. TNBC Twitter Chat
Learn about TNBC, the latest in treatment options, lifestyle modifications to lower risk of recurrence and more! Join Living Beyond Breast Cancer, Triple Negative Breast Cancer Foundation, and Triple Step for a live Twitter chat on March 3, 2014 at 7:30 p.m. EST.
Two interesting neoadjuvant clinical trials for patients with triple-negative breast cancer were presented:
(1) CALBG/Alliance 40603: This study randomized triple-negative breast cancer patients to receive carboplatin, a DNA-damaging chemotherapy, plus or minus bevacizumab, a drug that slows the growth of new blood vessels, in addition to standard dose-dense doxorubicin, cyclophosphamide, and paclitaxel (the AC-T regimen) and showed that the patients on both the carboplatin plus standard chemotherapy and carboplatin, bevacizumab plus standard chemotherapy had a greater chance of having little to no residual disease in the breast and axilla (or armpit) at the time of lumpectomy or mastectomy.
A Big THANK YOU to Total Beauty Shops for donating a percentage of proceeds from the Pink Embrace Collection to raise awareness for TNBC. To learn more and enter the Pink Embrace Sweepstakes for your chance to win, click here.
August 4, 2013
I have always been a hard-working person, trying to never let anyone down. I love being a mom to my teenage daughter and my three dogs. I have an amazing, supportive husband and we just celebrated our Anniversary of 20 years. I do everything in life to be that good person! I am dedicated to work and my family, paying my bills, going for regular check-ups, and being there for everyone else in their time of need. Basically, I'm just always doing what is RIGHT and GOOD! I now struggle with recently being diagnosed and going through the fight with breast cancer. Who knew that I would eventually find myself with triple negative breast cancer...what did I do wrong? Why me?
September 27, 2013
My breast cancer story has a little bit of a different twist than most. I was one who did not discover a lump on my breast. My discovery was via a lump under my armpit which made practicing Bikram Yoga very painful.
Men and women living with advanced breast cancer due to a BRCA1/2 gene mutation may qualify for a new clinical research study known as the BROCADE Study. This study will determine the safety and effectiveness of veliparib, an experimental anti-cancer drug, in combination with chemotherapy. You may qualify for the study if you are 18 years of age or older, have metastatic or locally recurrent breast cancer and a BRCA1 or 2 mutation, and have not received more than two prior cancer treatments for advanced breast cancer.
People who enroll in the study will be randomized (like flipping a coin) in a 1:1:1 ratio to one of three study treatment groups: veliparib with temozolomide, veliparib with carboplatin and paclitaxel, or placebo with carboplatin and paclitaxel. Temozolomide, carboplatin, and paclitaxel are chemotherapy drugs approved for use in routine cancer care. A placebo is a look-alike pill with no active ingredients. Participants may receive compensation or reimbursement for travel to and from the study center.
If you are interested in learning more about this study, talk to your oncologist, visit the BROCADE Study website at www.BROCADEStudy.com , or call + 1 855 5ONCOLOGY (+ 1 855 566 2656) to speak with an experienced study nurse to determine if the BROCADE Study is right for you.